Edition:
India

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

4.27USD
1:30am IST
Change (% chg)

$-0.17 (-3.83%)
Prev Close
$4.44
Open
$4.48
Day's High
$4.52
Day's Low
$4.23
Volume
20,378
Avg. Vol
125,294
52-wk High
$7.44
52-wk Low
$1.90

Summary

Name Age Since Current Position

David Mahoney

65 2019 Lead Independent Chairman of the Board

Neil McFarlane

47 2019 Chief Executive Officer, Director

Christopher Prentiss

45 2019 Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer

Adrian Quartel

2020 Chief Medical Officer

Vijay Shreedhar

49 2019 Chief Commercial Officer

John MacPhee

45 2013 Director

Anna Richo

60 2020 Director

Michael Bigham

62 2016 Independent Director

Martha Demski

67 2014 Independent Director

Mardi Dier

56 2018 Independent Director

William Ericson

61 2005 Independent Director

Ivan Lieberburg

70 2004 Independent Director

Biographies

Name Description

David Mahoney

Mr. David L. Mahoney serves as Lead Independent Chairman of the Board of the Company. Mr. Mahoney has served on the board of directors of Symantec Corporation, a publicly-traded software technology company since 2003, including as current chair of the Compensation and as former chair of the Nominating and Governance Committees. Mr. Mahoney also served as a member of the Audit Committee of Symantec from 2003 to 2011. Mr. Mahoney has served on the board of directors of Corcept Therapeutics Incorporated, a pharmaceutical company since 2004, including as a member of the Audit and as a chair of the Nominating and Governance Committees. He also serves on the boards of directors of San Francisco Museum of Modern Art, Mount Holyoke College and Mercy Corps, and is a Trustee of the Schwab/Laudus Family of Funds. From 1999 to 2001, Mr. Mahoney served as co-CEO of McKesson HBOC, Inc., a healthcare supply management and information technology company and as CEO of McKesson LLC, a healthcare management and connectivity company. He joined McKesson Corporation in 1990 as Vice President for Strategic Planning. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company, a management consulting firm, where he worked from 1981 to 1990. Mr. Mahoney holds a B.A. from Princeton University and an M.B.A. from Harvard University. We believe Mr. Mahoney’s extensive experience in pharmaceutical distribution, fiscal management, and in operating and advising technology companies qualifies him to serve on our Board of Directors.

Neil McFarlane

Mr. Neil McFarlane serves as Chief Executive Officer, Director of the Company. Mr. McFarlane has served as the Chief Operating Officer of Retrophin, Inc., a biopharmaceutical company, from August 2016 until May 2019, in which position he was responsible for global commercial operations, corporate development, patient services, and program and alliance management. Previously, Mr. McFarlane served as the Vice President, Bone business unit for UCB, Inc., a biopharmaceutical company, since 2013, in which role he was responsible for leading the global collaboration with Amgen, and from 2011 to 2013, Mr. McFarlane was the Vice President and General Manager of the US Immunology business unit at UCB, Inc. Prior to his positions at UCB, Mr. McFarlane held positions of increasing responsibility with Genzyme Corporation, a biotechnology company, and Sangstat Medical Corporation prior to its acquisition by Genzyme. Mr. McFarlane served in the United States Army Reserves and received his B.S. and M.S. in Nursing from the University of Florida. Adamas believes Mr. McFarlane’s position as our Chief Executive Officer and his extensive knowledge of the pharmaceutical industry qualifies him to serve on the Board.

Christopher Prentiss

Mr. Christopher B. Prentiss serves as Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company. Prior to joining Adamas, Mr. Prentiss was the Vice President, Finance and Controller at InterMune, Inc., a biotechnology company, from June 2013 to March 2015, where he was responsible for the management of the accounting function. Prior to that, Mr. Prentiss was Senior Director, Controller at Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, from May 2012 to June 2013, where he was responsible for the accounting and tax functions. From June 2005 to May 2012, Mr. Prentiss was at MannKind Corporation where he served in a variety of finance roles, most recently as Senior Director, Controller. Prior to joining MannKind, Mr. Prentiss was a Senior Manager at KPMG LLP in the assurance practice. Mr. Prentiss received a Bachelor’s of Science degree in Accounting from Loyola Marymount University, and a Masters of Business Administration from Indiana University. Mr. Prentiss is a CPA licensed in California.

Adrian Quartel

Mr. Adrian Quartel serves as Chief Medical Officer of the Company. Adrian brings over 20 years of global drug development and pharmaceutical experience, both in academia and industry. He was most recently global head of Medical Affairs at BioMarin, where he oversaw the launch of six products. Prior to BioMarin, Adrian held senior positions leading clinical development and as principal investigator for several studies at Chiltern. He also served in pharmacovigilance, clinical development, and medical affairs roles at Paraxel, Icon and, Astellas. Prior to joining the industry, Adrian worked as a clinical research fellow at UCLA Cedar Sinai and as a resident in cardio-thoracic surgery at Erasmus University Medical Center. Adrian received his medical degree from Erasmus University Medical School, Rotterdam, in the Netherlands, and his post graduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine in London. He is board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom.

Vijay Shreedhar

Mr. Vijay Shreedhar serves as Chief Commercial Officer of the Company. Prior to joining Adamas, Dr. Shreedhar served in a variety of sales and marketing roles of increasing responsibility in multiple therapeutic areas at Amgen, a biotechnology company, from August 2005 to May 2019. Most recently, he was Executive Director and Integrated Commercial Lead for the Multiple Myeloma franchise with responsibility for national sales, brand marketing and regional marketing teams. Dr. Shreedhar holds a Ph.D. in Oncology and Immunology from the University of Texas, M.D. Anderson Cancer Center and an MBA in Healthcare Management from the Wharton School at the University of Pennsylvania

John MacPhee

Mr. John MacPhee serves as Director of the Company. He has served as a member of our Board of Directors since May 2013 and provided consulting services to us from March 2011 to May 2013, and from February 2016 to December 2016. Since 2011, Mr. MacPhee has served as the Executive Director and CEO of The Jed Foundation, a non-profit organization. From 2005 to 2011, Mr. MacPhee served as Executive Vice President of Par Pharmaceutical, Inc. and President of Par’s Strativa Pharmaceuticals division, where he oversaw commercial operations, clinical development, medical affairs, alliance management, and business development. Previously, Mr. MacPhee worked at Forest Laboratories, Inc., where he led the launches of Celexa, Lexapro, and Namenda. Mr. MacPhee also serves as a board member for Blackthorn Therapeutics, a privately-held pharmaceutical company. Mr. MacPhee holds a B.A. from Columbia College, an M.B.A. from New York University, and an M.P.H. from Columbia University. We believe Mr. MacPhee’s extensive experience building successful specialty pharmaceutical companies and commercializing drug products qualifies him to serve on our Board of Directors.

Anna Richo

Ms. Anna S. Richo J.D. serves as Director of the Company. Ms. Richo's successful career path includes leadership roles in biotechnology and pharmaceutical companies as general counsel and leading compliance, intellectual property, and corporate litigation. Ms. Richo has previously been recognized as one of the 'Top 15 Women in Pharma'. She holds a bachelor's degree in industrial and labor relations from Cornell University and a J.D. degree from DePaul University, College of Law. She is a member of the Board of Trustees for DePaul University.

Michael Bigham

Mr. Michael F. Bigham serves as Independent Director of the Company. Mr. Bigham was appointed Executive Chairman of the board of directors of Paratek Pharmaceuticals, Inc., a biopharmaceutical company, in June 2019 and served as Paratek’s Chief Executive Officer and Chairman from June 2014 to June 2019. Mr. Bigham has more than 25 years of senior leadership experience in the biopharmaceutical industry. From 2003 to 2015, he was a General Partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare. From 2015 to 2018, he served as an Executive Partner at Abingworth LLP. Mr. Bigham also currently serves on the board of Tenneobio Inc., and in the past has held several directorships, including at Avila Therapeutics (where he was also the founding Chairman and CEO), Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Inmediata (Chairman) and Valeritas. Mr. Bigham was formerly Vice Chairman of Corixa Corporation, a publicly-traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publicly-traded oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead, Mr. Bigham was a Partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. Mr. Bigham received his B.S. from the University of Virginia and qualified as a C.P.A. before completing his M.B.A. at Stanford University.

Martha Demski

Ms. Martha J. Demski serves as Independent Director of the Company. From August 2011 to May 2017, Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc., now known as Ajinomoto Bio-Pharma Services, a fully-integrated contract development and manufacturing organization. From July 2008 to December 2010, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center (SKCC), a non-profit corporation that was engaged in biomedical research. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical Incorporated, a publicly traded biotech company from December 1988 to June 2004. Ms. Demski currently serves as Chair of the board of directors of Chimerix, Inc., a publicly traded biotech company. Ms. Demski also serves as a member of the board of directors of Equillium, Inc., a publicly traded biotech company where she serves as chair of the audit committee and a member of the compensation committee. Prior to 2018, Ms. Demski was a member of the board of directors, chair of the audit committee and member of the compensation committee, nominating and governance committee, and operating committee of Neothetics, Inc., a publicly-held biotechnology company that merged with Evofem Biosciences, Inc. in 2018. Ms. Demski is a National Association of Corporate Directors Board Governance Fellow and received the Director of the Year in Corporate Governance from the Corporate Directors Forum in 2017. Additionally, Ms. Demski has over 13 years of banking experience with Bank of America. Ms. Demski earned a B.A. from Michigan State University and M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance.

Mardi Dier

Ms. Mardi C. Dier serves as Independent Director of the Company. Ms. Dier has served as Executive Vice President and Chief Financial Officer of Portola Pharmaceuticals, Inc., a biopharmaceuticals company, since November 2013 after joining the company in August 2006, and was designated Chief Business Officer in November 2018. Ms. Dier also served as Portola’s interim Co-President from June 2018 to August 2018. At Portola, Ms. Dier has overseen the development of the accounting, finance, global supply chain, investor relations, communications, IT and facilities functions, and has led the raising of over $1.25 billion in capital. Ms. Dier was appointed to the board of directors of ORIC Pharmaceuticals, a privately held clinical stage oncology company, in March 2020, where she serves as chair of the audit committee. Previously, she served as Vice President of Investor Relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a Director in the West Coast investment banking practice at Prudential Securities, where she focused on biotechnology and other life sciences companies. Ms. Dier was previously at KPMG LLP in the audit department. She holds a B.S. in biology from Stanford University and an M.B.A. from The Anderson School at the University of California, Los Angeles. In 2013, Ms. Dier was recognized as one of the most influential Bay Area business women by the San Francisco Business Times and was a finalist for its Bay Area CFO of the Year Award.

William Ericson

Mr. William W. Ericson serves as Independent Director of the Company. Mr. Ericson has been a Managing Director of Wildcat Venture Partners, a venture capital firm, since 2015. In addition, Mr. Ericson has been a General Partner at Mohr Davidow Ventures, or MDV, a venture capital firm, since 2000. Prior to joining MDV, Mr. Ericson founded and operated Venture Law Group LLP’s Seattle office from 1996 to 2000. Mr. Ericson currently serves as a member of the board of directors of Pacific Biosciences of California, Inc., a publicly traded gene sequencing company, Northwestern University School of Law, and a number of MDV’s privately held portfolio companies. Mr. Ericson previously served as a member of the board of directors of Rocket Fuel Inc., a publicly traded digital advertising company, from 2008 to 2017. Mr. Ericson holds a B.S.F.S. from the School of Foreign Service at Georgetown University and a J.D. from Northwestern University School of Law.

Ivan Lieberburg

Dr. Ivan M. Lieberburg Ph.D. M.D. serves as Independent Director of the Company. Dr. Lieberburg has been a member of the Tavistock Group, a private equity firm, since 2009, and a managing director of Boxer Capital, since 2017, where he concentrates on health care and life sciences investment opportunities. From 1987 to 2009, Dr. Lieberburg was employed by Elan Pharmaceuticals, Inc. (formerly Athena Neurosciences, Inc.), where his most recent roles were as Executive Vice President, Corporate Office of Technology and Chief Medical Officer. Dr. Lieberburg holds an A.B. in Biology from Cornell University, a Ph.D. in Neurobiology from The Rockefeller University, and an M.D. from the University of Miami Leonard M. Miller School of Medicine. Dr. Lieberburg is board certified in internal medicine and endocrinology/metabolism. We believe Dr. Lieberburg’s executive experience in the life sciences industry and his medical training qualifies him to serve on our Board of Directors.

Basic Compensation

Name Fiscal Year Total

David Mahoney

264,876

Neil McFarlane

2,080,640

Christopher Prentiss

1,093,640

Adrian Quartel

--

Vijay Shreedhar

1,230,090

John MacPhee

67,705

Anna Richo

--

Michael Bigham

82,705

Martha Demski

94,705

Mardi Dier

77,705

William Ericson

84,705

Ivan Lieberburg

67,705
As Of  31 Dec 2019